Navigation Links
Pharmasset Reports Fiscal Second Quarter 2011 Financial Results
Date:4/25/2011

merase, thus inhibiting viral replication. We currently have three clinical-stage product candidates. PSI-7977, an unpartnered uracil nucleotide analog that is currently dosing in three Phase 2b studies in patients with HCV genotypes 1 through 6 and PSI-938, an unpartnered guanosine nucleotide analog which recently completed a 14-day monotherapy study and a 14-day combination study with PSI-7977. RG7128, a cytosine nucleoside analog for chronic HCV infection, is in two Phase 2b clinical studies in combination with Pegasys® plus Copegus® and one interferon free combination trial. These clinical studies are being conducted through a strategic collaboration with Roche.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Forward-Looking StatementsPharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:  Statements in this press release that are not historical facts are "forward-looking statements," that involve risks, uncertainties, and other important factors, including, without limitation,  the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates,  the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful, and the risk that any one or more of our product candidates will not be successfully developed and commercialized.  For a discussion of risks, uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended September 30, 2010 and our Quarterly Reports on Form 10-Q filed with the Securities an
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... March 29, 2015  Three-month paliperidone palmitate, an ... compared to placebo in patients with schizophrenia, according ... this week in the Journal of ... . Results of the study served as ... (NDA) filing for three-month paliperidone palmitate injection to ...
(Date:3/27/2015)... March 27, 2015 BioCorRx, Inc. ( ... Ana, California is a healthcare solutions organization, which ... estimated at $22 billion in the U.S. alone. The Company ... FDA-approved Naltrexone in a specially compounded form for outpatient surgical ... and New Zealand ) to ...
(Date:3/27/2015)... CHAPEL HILL, N.C. , March 27, 2015 /PRNewswire/ ... function is essential to meeting challenges in clinical development, ... and face tighter regulations, the Medical Affairs function is ... charted by mature markets. According to ... market study participants have a group dedicated to Medical ...
Breaking Medicine Technology:New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 2New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 3New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 4New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 6New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 7New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 8New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 9New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 10New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 11New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 12Small Cap IR Correction -- BioCorRx Inc. Positions Itself Through Strategic Partnerships To Gain Market Share Of The $22 Billion Substance Abuse Treatment Market In The U.S. 2Medical Affairs Capabilities Expanding in Emerging Marketplaces 2
... Feb. 2, 2011 WaferGen Biosystems, Inc. (OTC Bulletin ... analysis systems, today announced that it will present an overview of ... in New York City at the Waldorf Astoria Hotel, Tuesday, February ... webcast live and archived for 90 days and may be accessed ...
... 2011 Reportlinker.com announces that a new market research ... US Prebiotics Industry ... And European markets for Prebiotics in Metric Tons and ... the following product segments: Mannan-Oligosaccharide (MOS), Fructans (Fructo-Oligosaccaride (FOS), ...
Cached Medicine Technology:WaferGen to Present at 13th Annual BIO CEO and Investor Conference 2US Prebiotics Industry 2US Prebiotics Industry 3US Prebiotics Industry 4US Prebiotics Industry 5US Prebiotics Industry 6US Prebiotics Industry 7
(Date:3/28/2015)... Las Vegas, NV (PRWEB) March 28, 2015 ... correlate with a history of shoulder and elbow injuries, according ... for Sports Medicine’s ( AOSSM ) Specialty Day. , “Our ... associated with a 20% increase in likelihood of a history ... is associated with a 12% increase likelihood of a history ...
(Date:3/28/2015)... NV (PRWEB) March 28, 2015 Delaying ... not be necessary, according to research presented today at ... ) Specialty Day. , “Our study compared results for ... who underwent an additional glenohumeral joint capsule release procedure ... George Murrell MD, PhD, lead author from St. George ...
(Date:3/28/2015)... Francisco, California (PRWEB) March 28, 2015 Andrew ... for original 1960's Who psychedelic concert posters. The Who and ... New York on August 2, 1968. According to Hawley, “The ... playing many concert halls and college campuses. Perhaps the most ... performance with Jim Morrison and the Doors on August 2, ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Healthpointe’s otolaryngologists, ... nose and throat disorders, are now offering a ... common issue which is characterized by the presence of ... in 5 people, tinnitus is a prevalent symptom that ... while it is non-fatal, tinnitus can impede a person’s ...
(Date:3/28/2015)... ARDX will sponsor the 7th Annual Women’s ... the Chesapeake Conference Center in Chesapeake, Virginia. Each year, ... for women in the Hampton Roads region. The 2015 ... Lives. Women grow stronger through sharing their stories and ... year the WWC™ theme is T-talk where we will share ...
Breaking Medicine News(10 mins):Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2
... Consumers need answers to questions that loom large ... is at risk.A new discussion forum launching this week ... ask tough questions and get straight answers about health ... options after a job loss."People who lose their jobs ...
... news release, Your Finances or a Facelift? It,s ... & Co Ltd over PR Newswire, we are advised ... press release was issued inadvertently. The complete, corrected release ... To DownsizeLeading Image Enhancement Coach Wendy Lewis Explains the ...
... To prevent the rejection of newly transplanted ... weaken their entire immune systems. Such potentially life-saving ... to life-threatening infections. , Now researchers at ... School of Medicine and the UNC Lineberger Comprehensive ...
... 11, 2009 "The House of Representatives and the ... ,down payment, on health care reform in the economic ... the American College of Physicians, said today. ... agreement that will provide adequate funding for critical health ...
... Feb. 11 Mesa Laboratories, Inc. (Nasdaq: ... of Directors has declared a regular quarterly cash ... stock, payable on March 16, 2009 to shareholders ... February 27, 2009.Mesa Laboratories develops, acquires, manufactures and ...
... Fresenius Kabi Pty Ltd, one of Australia,s fastest growing ... System (Robotic IV Automation) - a self-contained unit for ... Systems (IH Systems) to consolidate its IV preparation. Pharmatel ... unit in June 2009. , The RIVA System and ...
Cached Medicine News:Health News:C4CC Education Fund Launches Discussion Forum for Consumers With Health Insurance Questions 2Health News:Your Facelift or Your Finances? It's Time To Downsize 2Health News:UNC study hints at new approaches to prevent transplant rejection 2Health News:UNC study hints at new approaches to prevent transplant rejection 3Health News:ACP commends Congress for including health care reform in economic stimulus legislation 2Health News:Australia's Leading Oncology Drug Compounder Chooses RIVA System 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: